GB9317686D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB9317686D0
GB9317686D0 GB939317686A GB9317686A GB9317686D0 GB 9317686 D0 GB9317686 D0 GB 9317686D0 GB 939317686 A GB939317686 A GB 939317686A GB 9317686 A GB9317686 A GB 9317686A GB 9317686 D0 GB9317686 D0 GB 9317686D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939317686A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Priority to GB939317686A priority Critical patent/GB9317686D0/en
Publication of GB9317686D0 publication Critical patent/GB9317686D0/en
Priority to ZA946262A priority patent/ZA946262B/xx
Priority to PCT/GB1994/001817 priority patent/WO1995005814A1/en
Priority to JP7507412A priority patent/JPH09501927A/ja
Priority to KR1019960700936A priority patent/KR100331978B1/ko
Priority to NZ269596A priority patent/NZ269596A/en
Priority to AU73907/94A priority patent/AU698785B2/en
Priority to EP94923817A priority patent/EP0714294A1/en
Priority to US08/602,814 priority patent/US5824673A/en
Priority to HU9600441A priority patent/HUT74947A/hu
Priority to FI960849A priority patent/FI960849A0/fi
Priority to TW083107611A priority patent/TW282401B/zh
Priority to CA002170253A priority patent/CA2170253A1/en
Priority to NO960754A priority patent/NO960754L/no
Priority to US09/802,523 priority patent/US6417182B1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB939317686A 1993-08-25 1993-08-25 Pharmaceutical compositions Pending GB9317686D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GB939317686A GB9317686D0 (en) 1993-08-25 1993-08-25 Pharmaceutical compositions
ZA946262A ZA946262B (en) 1993-08-25 1994-08-18 Pharmaceutical compositions
CA002170253A CA2170253A1 (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
AU73907/94A AU698785B2 (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
HU9600441A HUT74947A (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
KR1019960700936A KR100331978B1 (ko) 1993-08-25 1994-08-19 금속착체를포함하는의약조성물
NZ269596A NZ269596A (en) 1993-08-25 1994-08-19 Pharmaceutical use of ruthenium complexes having at least one site for coordination with nitric oxide
PCT/GB1994/001817 WO1995005814A1 (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
EP94923817A EP0714294A1 (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
US08/602,814 US5824673A (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
JP7507412A JPH09501927A (ja) 1993-08-25 1994-08-19 金属錯体を含んで成る医薬組成物
FI960849A FI960849A0 (fi) 1993-08-25 1994-08-19 Metallikomplekseja sisältäviä farmaseuttisia koostumuksia
TW083107611A TW282401B (enExample) 1993-08-25 1994-08-19
NO960754A NO960754L (no) 1993-08-25 1996-02-23 Farmasöytiske blandinger omfattende metall-komplekser
US09/802,523 US6417182B1 (en) 1993-08-25 2001-03-09 Pharmaceutical compositions comprising metal complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939317686A GB9317686D0 (en) 1993-08-25 1993-08-25 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB9317686D0 true GB9317686D0 (en) 1993-10-13

Family

ID=10741021

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939317686A Pending GB9317686D0 (en) 1993-08-25 1993-08-25 Pharmaceutical compositions

Country Status (14)

Country Link
US (1) US5824673A (enExample)
EP (1) EP0714294A1 (enExample)
JP (1) JPH09501927A (enExample)
KR (1) KR100331978B1 (enExample)
AU (1) AU698785B2 (enExample)
CA (1) CA2170253A1 (enExample)
FI (1) FI960849A0 (enExample)
GB (1) GB9317686D0 (enExample)
HU (1) HUT74947A (enExample)
NO (1) NO960754L (enExample)
NZ (1) NZ269596A (enExample)
TW (1) TW282401B (enExample)
WO (1) WO1995005814A1 (enExample)
ZA (1) ZA946262B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417182B1 (en) * 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
ES2238074T3 (es) * 1994-05-11 2005-08-16 Jes Olesen Uso de depuradores, inhibidores o antagonistas de no en el tratamiento de la migraña.
NZ285648A (en) * 1994-05-13 1999-08-30 Monsanto Co Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
DE19860289C2 (de) 1998-12-21 2003-11-13 Schering Ag Neue Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
CA2367282A1 (en) * 1999-03-19 2000-09-28 Simon Fricker Pharmaceutical compositions comprising metal complexes
EP1212459A2 (en) * 1999-08-25 2002-06-12 Clarity Biosciences, Inc. Identifying organisms by detecting intronic nucleic acid or encoded proteins
US7335383B2 (en) * 2001-01-16 2008-02-26 The Regents Of The University Of Michigan Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood
US7128904B2 (en) * 2001-01-16 2006-10-31 The Regents Of The University Of Michigan Material containing metal ion ligand complex producing nitric oxide in contact with blood
EP1370679B1 (en) * 2001-03-01 2011-10-05 Clarity Biosciences, Inc. Methods of making and uses of compositions that modulate intronic region-encoded protein function
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2319518A1 (en) * 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CN1318430C (zh) * 2003-04-24 2007-05-30 钟文远 一类稀土配合物及其制备方法和在制备治疗肿瘤药物中的应用
KR20060125790A (ko) * 2003-11-07 2006-12-06 가부시키가이샤 시테크 뇌경색의 예방 및/또는 치료를 위한 의약
US20060008529A1 (en) * 2004-07-12 2006-01-12 Meyerhoff Mark E Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
WO2007005758A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Methods , compositions and devices for promoting angiogenesis
CN101378792A (zh) * 2005-12-02 2009-03-04 密执安大学评议会 聚合物组合物、涂层和装置及其制备和使用方法
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US20080119002A1 (en) * 2006-11-17 2008-05-22 Charles Grosjean Substrate contact for a MEMS device
US8597563B2 (en) 2008-07-11 2013-12-03 Rohm And Haas Company Recycled thermoplastic composition comprising waste thermoset material and methods of making
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
DE102010014411A1 (de) 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
WO2012138988A2 (en) * 2011-04-07 2012-10-11 The Research Foundation Of The City University Of New York Organometallic anti-cancer complexes
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008537A1 (de) 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482811A (fr) * 1960-01-26 1967-06-02 Australian Nat University Pers Nouveaux complexes métallifères d'agents de coordination homogènes, et leur procédé de préparation
AU570826B2 (en) * 1984-07-24 1988-03-24 Asta-Pharma Aktiengesellschaft Ruthenium compounds having a tumor inhibiting activity
WO1986000804A1 (fr) * 1984-07-24 1986-02-13 Byk Gulden Lomberg Chemische Fabrik Gesellschaft M Compositions de ruthenium a effet inhibiteur de tumeurs
US5157032A (en) * 1985-01-18 1992-10-20 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents and probes to DNA
IT1230145B (it) * 1989-05-05 1991-10-14 Boehringer Biochemia Srl Complessi di rutenio (iii) come agenti antineoplastici.

Also Published As

Publication number Publication date
NO960754L (no) 1996-04-23
HU9600441D0 (en) 1996-04-29
AU698785B2 (en) 1998-11-05
KR100331978B1 (ko) 2002-09-26
ZA946262B (en) 1995-03-20
FI960849L (fi) 1996-02-23
EP0714294A1 (en) 1996-06-05
US5824673A (en) 1998-10-20
NO960754D0 (no) 1996-02-23
AU7390794A (en) 1995-03-21
HUT74947A (en) 1997-03-28
JPH09501927A (ja) 1997-02-25
FI960849A7 (fi) 1996-02-23
FI960849A0 (fi) 1996-02-23
NZ269596A (en) 1997-05-26
KR960703609A (ko) 1996-08-31
CA2170253A1 (en) 1995-03-02
WO1995005814A1 (en) 1995-03-02
TW282401B (enExample) 1996-08-01

Similar Documents

Publication Publication Date Title
ZA946262B (en) Pharmaceutical compositions
HU9402974D0 (en) Pharmaceutical composition
GB9224855D0 (en) Pharmaceutical compositions
GB9308014D0 (en) Pharmaceutical compositions
GB9317610D0 (en) Pharmaceutical compositions
IL110201A0 (en) Novel pharmaceutical compositions
ZA945930B (en) Pharmaceutical composition
PL314036A1 (en) Pharmaceutical composition
GB9209874D0 (en) Pharmaceutical compositions
GB9317504D0 (en) Pharmaceutical compositions
CA2100836A1 (en) Pharmaceutical composition
ZA945752B (en) Pharmaceutical composition
GB9318880D0 (en) Pharmaceutical composition
HU9401771D0 (en) Pharmaceutical compositions cintaining ipsapiron
GB9226377D0 (en) Pharmaceutical compositions
GB9211276D0 (en) Pharmaceutical compositions
GB9420129D0 (en) Pharmaceutical compositions
GB9306570D0 (en) Pharmaceutical compositions
GB9321203D0 (en) Pharmaceutical compositions
GB9306582D0 (en) Pharmaceutical compositions
ZA946073B (en) Pharmaceutical compositions
GB9303238D0 (en) Pharmaceutical compositions
ZA933031B (en) Pharmaceutical compositions
GB9311058D0 (en) Pharmaceutical compositions
GB9304784D0 (en) Pharmaceutical compositions